WO1999064065A3 - Tumour therapy and imaging - Google Patents

Tumour therapy and imaging Download PDF

Info

Publication number
WO1999064065A3
WO1999064065A3 PCT/GB1999/001870 GB9901870W WO9964065A3 WO 1999064065 A3 WO1999064065 A3 WO 1999064065A3 GB 9901870 W GB9901870 W GB 9901870W WO 9964065 A3 WO9964065 A3 WO 9964065A3
Authority
WO
WIPO (PCT)
Prior art keywords
agent
imaging
tumour
tumour therapy
patient
Prior art date
Application number
PCT/GB1999/001870
Other languages
French (fr)
Other versions
WO1999064065A2 (en
Inventor
Kenneth Dawson Bagshawe
Original Assignee
Enzacta R & D Ltd
Kenneth Dawson Bagshawe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzacta R & D Ltd, Kenneth Dawson Bagshawe filed Critical Enzacta R & D Ltd
Priority to AU59469/99A priority Critical patent/AU5946999A/en
Publication of WO1999064065A2 publication Critical patent/WO1999064065A2/en
Publication of WO1999064065A3 publication Critical patent/WO1999064065A3/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

A method of combating a tumour in a patient, the method comprising administering to the patient a) an agent which tolerizes the patient to a said tumour selective agent or to an agent which interacts selectively with the said tumour selective agent; b) a tumour selective agent which comprises a polypeptide; and c) at least one further agent which interacts selectively with the said tumour selective agent.
PCT/GB1999/001870 1998-06-11 1999-06-11 Tumour therapy and imaging WO1999064065A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU59469/99A AU5946999A (en) 1998-06-11 1999-06-11 Tumour therapy and imaging

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9812550.3A GB9812550D0 (en) 1998-06-11 1998-06-11 Tumour therapy and imaging
GB9812550.3 1998-06-11

Publications (2)

Publication Number Publication Date
WO1999064065A2 WO1999064065A2 (en) 1999-12-16
WO1999064065A3 true WO1999064065A3 (en) 2000-06-29

Family

ID=10833545

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/001870 WO1999064065A2 (en) 1998-06-11 1999-06-11 Tumour therapy and imaging

Country Status (3)

Country Link
AU (1) AU5946999A (en)
GB (1) GB9812550D0 (en)
WO (1) WO1999064065A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201308363D0 (en) * 2013-05-09 2013-06-19 Bagshawe Kenneth D Tumour therapy
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
RU2744860C2 (en) 2015-12-30 2021-03-16 Кодиак Сайенсиз Инк. Antibodies and their conjugates
WO2018071435A1 (en) 2016-10-11 2018-04-19 Microdose Therapeutx, Inc. Inhaler and methods of use thereof
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63219374A (en) * 1987-03-09 1988-09-13 Takara Shuzo Co Ltd Chemically modified carboxypeptidase and use thereof
WO1989010140A1 (en) * 1988-04-22 1989-11-02 Cancer Research Campaign Technology Limited Further improvements relating to drug delivery systems
WO1991001758A1 (en) * 1989-08-07 1991-02-21 Debiopharm S.A. Biologically active drug polymer derivatives
WO1998024478A2 (en) * 1996-11-30 1998-06-11 Enzacta R & D Limited Tumour therapy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63219374A (en) * 1987-03-09 1988-09-13 Takara Shuzo Co Ltd Chemically modified carboxypeptidase and use thereof
WO1989010140A1 (en) * 1988-04-22 1989-11-02 Cancer Research Campaign Technology Limited Further improvements relating to drug delivery systems
WO1991001758A1 (en) * 1989-08-07 1991-02-21 Debiopharm S.A. Biologically active drug polymer derivatives
WO1998024478A2 (en) * 1996-11-30 1998-06-11 Enzacta R & D Limited Tumour therapy

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
ABUCHOWSKI A ET AL: "CANCER THERAPY WITH CHEMICALLY MODIFIED ENZYMES.I. ANTITUMOR PROPERTIES OF POLYETHYLENE GLYCOL-ASPARAGINASE CONJUGATES", CANCER BIOCHEMISTRY BIOPHYSICS, vol. 7, 1 January 1984 (1984-01-01), pages 175 - 186, XP002055709 *
BRYGIER, JEANNE ET AL: "Preparation and preliminary characterization of poly ( ethylene glycol )-pepstatin conjugate", APPL. BIOCHEM. BIOTECHNOL. 1994, VOL. 47, NO. 1, PAGE(S) 1-10, XP002121730 *
C DELGADO ET AL: "Enhanced tumour specificity of an anti-carcinoembryonic antigen Fab' fragment by poly(ethylene glycol) (PEG) modification", BRITISH JOURNAL OF CANCER, vol. 73, no. 2, 1 January 1996 (1996-01-01), pages 175 - 182, XP002084719 *
E ENOAMOOQUAYE ET AL: "Altered biodistribution of an antibody-enzyme conjugate modified with polyethylene-glycol", BRITISH JOURNAL OF CANCER, vol. 73, no. 11, 1 June 1996 (1996-06-01), pages 1323 - 1327, XP002084718 *
NUCCI M L ET AL: "THE THERAPEUTIC VALUE OF POLY(ETHYLENE GLYCOL)-MODIFIED PROTEINS", ADVANCED DRUG DELIVERY REVIEWS, vol. 6, no. 2, 1 March 1991 (1991-03-01), pages 133 - 151, XP002064123 *
PATENT ABSTRACTS OF JAPAN vol. 013, no. 011 (C - 558) 11 January 1989 (1989-01-11) *
PEDLEY R B ET AL: "THE POTENTIAL FOR ENHANCED TUMOUR LOCALISATION BY POLY(ETHYLENE GLYCOL) MODIFICATION OF ANTI-CEA ANTIBODY", BRITISH JOURNAL OF CANCER, vol. 70, 1994, pages 1126 - 1130, XP000575990 *
PERRON MJ ET AL: "Activation of methotrexate-phenylalanine by monoclonal antibody-- carboxypeptidase A conjugate for the specific treatment of ovarian cancer in vitro.", BR J CANCER, FEB 1996, VOL. 73, NO. 3, PAGE(S) 281-287, XP002121729 *
POOL R: "PEG-TREATED ENZYMES ARE NEARLY INVISIBLE TO THE IMMUNE SYSTEM", SCIENCE, vol. 248, no. 4953, 20 April 1990 (1990-04-20), pages 305, XP000128555 *
SHARMA S K: "ACCELERATED CLEARANCE SYSTEMS", ADVANCED DRUG DELIVERY REVIEWS, vol. 22, 1 January 1996 (1996-01-01), pages 315 - 324, XP002064129 *

Also Published As

Publication number Publication date
WO1999064065A2 (en) 1999-12-16
GB9812550D0 (en) 1998-08-05
AU5946999A (en) 1999-12-30

Similar Documents

Publication Publication Date Title
AU1393000A (en) 1,4-diazabicyclo(3.2.2)nonane derivatives, their preparation and therapeutic application
WO2006046080A8 (en) Pegylated liposomal doxorubicin in combination with ecteinescidin 743
AU2002231691A1 (en) Novel medicament compositions based on anticholinesterase drugs and on ciclesonides
ITRM920412A0 (en) HETEROPROSTANOIDS, PROCEDURE FOR THEIR PREPARATION AND THEIR THERAPEUTIC USE.
HK1041448A1 (en) Storable active substance concentrate with formoterol.
MXPA97002401A (en) Antiinflammatory agent for external use.
AU2990695A (en) Mucin-derived proteins for the diagnosis, imaging, and therapy of human cancer
AU9598198A (en) Method and apparatus for improving human physical performance, training for athletic activities, preventing injury, physical therapy or the like
CA2294921A1 (en) Levobupivacaine and its use
AU6246199A (en) Human interleukin-b50, therapeutic uses
AU2001264042A1 (en) 1,4-diazabicyclo(3.2.2)nonane-phenylisoxazole derivatives, preparation and therapeutic use thereof
IL129927A0 (en) 1,4-Diazabicyclo (2.2.2) oct-2-ylmethyl derivatives their preparation and therapeutic application
WO1999064065A3 (en) Tumour therapy and imaging
WO1997026918A3 (en) Ligand directed enzyme prodrug therapy
EP0967276A3 (en) Anti-tumor agent comprising salmosin
WO1997026867A3 (en) Solid instant-release forms of administration and process for producing the same
ZA974869B (en) Ortho-substituted benzoylguanidines, process for their preparation, their use as medicament or diagnostic, and medicament comprising them.
ZA200007111B (en) Methods and devices for providing prolonged drug therapy.
ZA976619B (en) Benzimidazole derivatives, their preparation and their therapeutic applications.
WO1999053064A3 (en) Methods of delivering glp-1
WO2002066513A3 (en) Human circulating lekti fragments hf7072, hf7638 and hf14448 and use thereof
AU2002340728A1 (en) Tt virus sequences in human tumoral tissue, agent for the detection thereof and tumoral therapy
TR199700144A2 (en) Ortho-substituted benzoylguanidines, the method, drug or diagnostic use for their manufacture and medicament containing them.
ZA974607B (en) Bis-ortho-substituted benzoylguanidines, processes for their preparation, their use as a medicament or diagnostic, and medicament comprising them.
AU3300397A (en) Cyclin-c variants, and diagnostic and therapeutic uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BR CA CN ID IN JP KR MX US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU BR CA CN ID IN JP KR MX US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 09787311

Country of ref document: US

122 Ep: pct application non-entry in european phase